Inhibition of B7-H3 by Enoblituzumab Elicits Antitumor Immune Modulation in Both Innate and Adaptive Immunity

B7-H3, a B7 family member, is widely expressed in multiple cancers and is associated with poor clinical prognosis. Enoblituzumab (MGA271 or TJ271) is an Fc-optimized antibody targeting B7-H3 with enhanced ADCC and ADCP activities. Here we further evaluated the immuno-modulatory function of TJ271 to explore new mechanism for cancer treatment.